Garofalo, M.
Bonanno, S.
Marcuzzo, S.
Pandini, C.
Scarian, E.
Dragoni, F.
Di Gerlando, R.
Bordoni, M.
Parravicini, S.
Gellera, C.
Masson, R.
Dosi, C.
Zanin, R.
Pansarasa, O.
Cereda, C.
Berardinelli, A.
Gagliardi, S.
Funding for this research was provided by:
Ministero della Salute (Ricerca Corrente 2022-2024)
Article History
Received: 13 July 2023
Accepted: 5 September 2023
First Online: 13 September 2023
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the Helsinki declaration and its later amendments or comparable ethical standards. The study design was examined by the IRBs of the enrolling institutions. The study protocol to obtain CSF from patients and was approved by the Ethical Committee of the IRCCS Mondino Foundation (Pavia, Italy) (Code: p-20190085117), and by the Fondazione IRCCS Istituto Neurologico Carlo Besta Research Ethical (Project identification code 92/2019, 16 January 2019). Informed consent was obtained from parents or legal tutors of all subjects involved in the study.
: SB received honoraria as invited speaker, advisory board activities, and compensation for travel and congress participation from Sanofi Genzyme, Biogen, Roche and Alexion. RZ received funds for travel, congress participation and advisory board activities from Biogen and Roche. CD received consultancy fees from Novartis Gene Therapies. RM was PI of SMA clinical trials for Roche, Avexis/Novartis Gene Therapies, Novartis, Biogen, and received consultancy fees from Roche, Novartis Gene Therapies, Biogen. The other authors declare no conflict of interest.